GenoFocus Valuation
| 187420 Stock | 4,050 165.00 3.91% |
At this time, the firm appears to be overvalued. GenoFocus retains a regular Real Value of USD3428.25 per share. The prevalent price of the firm is USD4050.0. Our model calculates the value of GenoFocus from evaluating the firm fundamentals such as Current Valuation of 231.24 B, return on equity of -24.42, and Return On Asset of -0.0291 as well as inspecting its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that GenoFocus' price fluctuation is very steady at this time. Calculation of the real value of GenoFocus is based on 3 months time horizon. Increasing GenoFocus' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since GenoFocus is currently traded on the exchange, buyers and sellers on that exchange determine the market value of GenoFocus Stock. However, GenoFocus' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 4050.0 | Real 3428.25 | Hype 4050.0 | Naive 4193.66 |
The real value of GenoFocus Stock, also known as its intrinsic value, is the underlying worth of GenoFocus Company, which is reflected in its stock price. It is based on GenoFocus' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of GenoFocus' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of GenoFocus helps investors to forecast how GenoFocus stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of GenoFocus more accurately as focusing exclusively on GenoFocus' fundamentals will not take into account other important factors: GenoFocus Total Value Analysis
GenoFocus is presently forecasted to have takeover price of 231.24 B with market capitalization of 132.88 B, debt of 26.94 B, and cash on hands of 25.11 B. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the GenoFocus fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
231.24 B | 132.88 B | 26.94 B | 25.11 B |
GenoFocus Investor Information
About 34.0% of the company shares are owned by insiders or employees . The company had not issued any dividends in recent years. GenoFocus had 2:1 split on the 19th of March 2018. Based on the key indicators related to GenoFocus' liquidity, profitability, solvency, and operating efficiency, GenoFocus is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.GenoFocus Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. GenoFocus has an asset utilization ratio of 21.83 percent. This suggests that the Company is making USD0.22 for each dollar of assets. An increasing asset utilization means that GenoFocus is more efficient with each dollar of assets it utilizes for everyday operations.GenoFocus Ownership Allocation
GenoFocus has a total of 21.54 Million outstanding shares. GenoFocus secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.GenoFocus Profitability Analysis
The company reported the revenue of 25.87 B. Net Loss for the year was (8.53 B) with profit before overhead, payroll, taxes, and interest of 6.06 B.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates GenoFocus' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in GenoFocus and how it compares across the competition.
About GenoFocus Valuation
The stock valuation mechanism determines GenoFocus' current worth on a weekly basis. Our valuation model uses a comparative analysis of GenoFocus. We calculate exposure to GenoFocus's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of GenoFocus's related companies.8 Steps to conduct GenoFocus' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates GenoFocus' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct GenoFocus' valuation analysis, follow these 8 steps:- Gather financial information: Obtain GenoFocus' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine GenoFocus' revenue streams: Identify GenoFocus' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research GenoFocus' industry and market trends, including the size of the market, growth rate, and competition.
- Establish GenoFocus' growth potential: Evaluate GenoFocus' management, business model, and growth potential.
- Determine GenoFocus' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate GenoFocus' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for GenoFocus Stock analysis
When running GenoFocus' price analysis, check to measure GenoFocus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GenoFocus is operating at the current time. Most of GenoFocus' value examination focuses on studying past and present price action to predict the probability of GenoFocus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GenoFocus' price. Additionally, you may evaluate how the addition of GenoFocus to your portfolios can decrease your overall portfolio volatility.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |